Brief: Seelos Therapeutics Experimental Treatment For Suicidal Behaviour Fails In Mid-Stage Study

Seelos Therapeutics

20/09/2023 12:21

Sept 20 (Reuters) - Seelos Therapeutics Inc  SEEL.O :
    * SEELOS THERAPEUTICS ANNOUNCES TOP LINE RESULTS FROM
SLS-002
PHASE II STUDY IN ADULTS WITH MAJOR DEPRESSIVE DISORDER AT
IMMINENT RISK OF SUICIDE
    * SEELOS THERAPEUTICS INC: SLS-002 WAS WELL-TOLERATED, WITH
NO
EVIDENCE OF NEW OR UNIQUE ADVERSE EVENTS AND THERE WERE NO
DEATHS REPORTED IN STUDY
    * SEELOS THERAPEUTICS INC - DUE TO LIMITED SAMPLE SIZE,
STUDY DID
NOT MEET PRE-DEFINED PRIMARY ENDPOINT
    * SEELOS THERAPEUTICS INC - HOWEVER ANALYSES SHOWED STUDY
WOULD
HAVE ACHIEVED STATISTICAL SIGNIFICANCE FOR MAIN GOAL, HAD STUDY
REACHED FULL ENROLLMENT

Source text for Eikon:  ID:nPn6z9knBa 
Further company coverage:  SEEL.O 

 ((Reuters.Briefs@thomsonreuters.com;))